products: what’s new in 2018 · 1.e+05 1.e+08 1.e+11 1.e+14 1.e+17 24h 48h 72h 96h r [Ω. cm 2]...
TRANSCRIPT
Epithelix Sàrl 18, Chemin des Aulx – CH-1228 Plan-les-Ouates – Genève – Switzerland
Tel: +41 (0) 22 794 65 15 / Fax: +41 (0) 22 794 65 17 [email protected] – www.epithelix.com
Products: What’s New in 2018
3D ALI airway epithelia
long shelf-life, fully differentiated, ready-to-use
MucilAir™ (-HF) and SmallAir™ (-HF) available from:
Primary cells from single donor or “pool-of-donors”
24 or 96 well format
Different anatomical origins: Nasal, Tracheal, Bronchial and Small Airways (new)
Several pathologies:
- Normal (Controls) - Asthma
- COPD (Chronic Obstructive Pulmonary Disease) - Allergic Rhinitis
- CF (Cystic Fibrosis – several mutations available)
Epithelix Sàrl 18, Chemin des Aulx – CH-1228 Plan-les-Ouates – Genève – Switzerland
Tel: +41 (0) 22 794 65 15 / Fax: +41 (0) 22 794 65 17 [email protected] – www.epithelix.com
Currently available products
Human Airway Tissues
Description Ref # Description Ref #
Mu
cilA
ir™
MucilAir™ MucilAir™ Pool of Donors MucilAir™-Asthma MucilAir™-Allergic Rhinitis MucilAir™-Smoker MucilAir™-COPD MucilAir™-CF
EP01MD EP02MP EP03MD EP04MD EP05MD EP06MD EP07MD
MucilAir™-HF MucilAir™-HF Pool of Donors MucilAir™-HF-Asthma MucilAir™-HF Allergic Rhinitis MucilAir™-HF-Smoker MucilAir™-HF-COPD MucilAir™-HF-CF
EP11MD EP12MP EP13MD EP14MD EP15MD EP16MD EP17MD
Description Ref # Description Ref #
Sm
all
Air
™
SmallAir™ SmallAir™-Asthma SmallAir™-Allergic Rhinitis SmallAir™-Smoker SmallAir™-COPD SmallAir™-CF
EP21SA EP23SA EP24SA EP25SA EP26SA EP27SA
SmallAir™-HF SmallAir™-HF-Asthma SmallAir™-HF-Allergic Rhinitis SmallAir™-HF-Smoker SmallAir™-HF-COPD SmallAir™-HF-CF
EP31SA EP33SA EP34SA EP35SA EP36SA EP37SA
MucilAir™ culture medium (125mL) MucilAir™ culture medium (500mL)
EP40MM EP41MM
SmallAir™ culture medium (125mL) SmallAir™ culture medium (500mL)
EP42SA EP43SA
Primary Human Cells & Extracts
Pri
mary
Hu
ma
n C
ells
Available from Nose, Trachea,
Bronchi and Small Airways
hAEC / hSAEC hAEC / hSAEC - Asthma hAEC / hSAEC - Allergic rhinitis hAEC / hSAEC - Smoker hAEC / hSAEC - COPD hAEC / hSAEC - CF
Human Pulmonary Fibroblasts
Ref #
EP51AB / EP61SA EP53AB / EP63SA EP54AB / EP64SA EP55AB / EP65SA EP56AB / EP66SA EP57AB / EP67SA
EP91AB
hAEC Culture Medium (500mL) hSAEC Culture Medium (500mL)
EP44AM EP45SA
Ce
lls
&
Tis
su
es
Ex
tra
cts
Mucin, Cell Pellet, Histology, ADN, ARN or protein extract, etc.
On Request Please Contact Us
Epithelix Sàrl 18, Chemin des Aulx – CH-1228 Plan-les-Ouates – Genève – Switzerland
Tel: +41 (0) 22 794 65 15 / Fax: +41 (0) 22 794 65 17 [email protected] – www.epithelix.com
Currently available in vitro Testing Services
Contract us to perform the following Acute, Long-term and Chronic in vitro studies:
Cilia Beating Frequency & Mucociliary Clearance Monitoring
Do your compounds increase or decrease the Ciliary Beat Frequency (CBF) or impact the
mucociliary clearance (MCC)? Is it increasing/decreasing or desynchronizing the cilia beating?
The effects of your compounds can be assessed in real time or
high throughput in a non-invasive manner on MucilAir™ and
SmallAir™. CBF is monitored with digital video files of motile
ciliated respiratory epithelial cells through a high-speed digital
video recorder. The mucociliary clearance is monitored using a
fully automated video-microscopy based setup. Microbeads of 30
microns are seeded onto the apical surface, then are then tracked
using specialized software allowing the calculation of their
velocities.
Cilia Frequency Distribution Microbeads tracking
Comparison of particles velocities between
MucilAir™-Normal and MucilAir™-CF
Normal CF
Epithelix Sàrl 18, Chemin des Aulx – CH-1228 Plan-les-Ouates – Genève – Switzerland
Tel: +41 (0) 22 794 65 15 / Fax: +41 (0) 22 794 65 17 [email protected] – www.epithelix.com
0
100
200
300
400
500
1.E+02
1.E+05
1.E+08
1.E+11
1.E+14
1.E+17
24H 48H 72H 96H
TEER
[Ω
.cm
2 ]
[CFU
/ M
uci
lAir
™]
Pseudomonas aeruginosa growth and TEER on MucilAir™
TEER w/o Meronem TEER with Meronem
CFU w/o Meronem CFU with Meronem
A relevant and reliable in vitro cell model for testing
novel antivirals (new)
A panel of clinical rhinovirus (RV), respiratory enterovirus (EV), influenza virus (Flu), respiratory
syncytial virus (RSV) and coronavirus (HCoV) specimens are all capable of productive infection in
MucilAir™ (Essaidi-Laziosi et al., JACI, 2017). Rupintrivir and Oseltamivir efficiently inhibit the
replication of rhinoviruses and influenza viruses, respectively. Thus, MucilAir™ is a relevant, reliable,
and convenient tool for testing novel anti-viral drugs against the respiratory viruses, including the most
challenging ones.
An in vitro platform to evaluate novel antibiotics against
respiratory bacterial infections (new)
Respiratory bacterial infections cause mild to severe diseases worldwide. To develop new therapies,
relevant human models are mandatory. MucilAir™ and SmallAir™ replicate not only the barrier
function, but also the innate defense mechanisms of human airway epithelium including mucus
production, mucociliary clearance, production and secretion of anti-microbial peptides. Many end-
points like Trans Epithelial Electrical Resistance (TEER) and bacterial growth (Colony Forming Unit:
CFU) can be monitored all along the infection to predict prevention of (i) cytotoxicity, (ii) disruption
of barrier function and (iii) impairment of cilia activity.
Available clinical strains for drug screening
Available strains for drug screening assay
Time course of replication of respiratory viruses